Pharmanest

Pharmanest initiates phase I SHACT trial

Monday, April 30, 2012

Pharmanest, a Stockholm-based pharmaceutical company, has dosed its first patient has in an open label pharmacokinetic phase I study with its drug candidate SHACT, a product developed for pain relief in connection with intrauterine device (IUD) insertion.

[Read More]